DEFA14A: Nordson to Acquire Atrion Corporation for $800 Million, Expanding Medical Portfolio

Nordson Corporation announced a definitive agreement to acquire Atrion Corporation for $460 per share in cash, valuing the company at approximately $800 million.

Summary

• Nordson Corporation has agreed to acquire Atrion Corporation for $460 per share in cash, representing an enterprise value of approximately $800 million.
• The acquisition is valued at 15 times Atrion's estimated 2024 EBITDA, including synergies expected within the first two years.
• Atrion, with approximately $169 million in annual revenue in 2023, specializes in medical infusion fluid delivery and cardiovascular solutions.
• The deal is expected to close before the end of Nordson's fiscal year 2024, pending regulatory and stockholder approvals.
• Nordson will fund the acquisition through a combination of cash on hand and newly issued financial debt.
• The transaction is projected to result in a net debt to EBITDA leverage ratio of 2-2.5X as Nordson exits fiscal year 2024.
• Nordson expects a high-single digit return on invested capital (ROIC) in year five.
• Atrion's portfolio includes Halkey Roberts (infusion fluid delivery), Atrion Medical (interventional inflation devices), and Quest Medical (myocardial protection devices).

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the strategic acquisition, expected synergies, and expansion into growing medical markets. The financial details, including the valuation and funding plan, appear reasonable and well-structured.

Positives

• The acquisition expands Nordson's medical portfolio into new markets and therapies.
• Atrion's product portfolio is highly complementary to Nordson's existing customer base and core competencies.
• The deal broadens Nordson's exposure to higher-growth medical end markets with recurring revenue streams.
• Nordson expects to leverage Atrion's FDA-registered facilities for future growth.
• Significant operational synergies are anticipated through Nordson's NBS Next growth framework.
• Atrion's strong patent portfolio and product pipeline offer future product development opportunities.

Negatives

• The transaction will increase Nordson's debt, with a projected net debt to EBITDA leverage ratio of 2-2.5X as they exit fiscal 2024.
• The acquisition is subject to regulatory and stockholder approvals, which could delay or prevent the deal from closing.
• Integration risks exist, and Nordson may not be able to successfully integrate Atrion's operations and achieve expected synergies.

Risks

• The transaction is subject to regulatory and stockholder approvals.
• There are risks associated with integrating Atrion's operations and achieving expected synergies.
• The acquisition could disrupt management time from ongoing business operations.
• The announcement of the transaction could have adverse effects on the market price of Atrion's or Nordson's common shares.
• The transaction could have an adverse effect on the parties' business relationships and their ability to retain customers and key personnel.
• Unexpected future capital expenditures could impact financial performance.
• Potential litigation relating to the transaction could be instituted against Atrion and/or Nordson.
• Changes in economic conditions, supply chain disruptions, and other external factors could impact the combined company's performance.

Future Outlook

The transaction is expected to close by the end of Nordson's fiscal year 2024, pending regulatory and stockholder approvals, and Nordson anticipates leveraging Atrion's facilities for future growth and achieving operational synergies.

Management Comments

• Sundaram Nagarajan, president and chief executive officer of Nordson Corporation, said, 'Over nearly 15 years, Nordson has built a strong medical portfolio through organic and acquisitive growth.'
• Sundaram Nagarajan stated, 'We have long admired Atrion's technology portfolio, and today's announcement represents a step forward in expanding our medical offerings for our customers.'
• Stephen Lovass, executive vice president, Nordson Medical and Fluid Solutions segment, added, 'In addition to its strong product and patent portfolios, Atrion's highly talented organization, as well as its three FDA registered design and manufacturing facilities, will be important additions to Nordson MEDICAL.'

Industry Context

This acquisition reflects a trend of consolidation in the medical device industry, where companies are seeking to expand their product portfolios and market reach through strategic acquisitions. Nordson's move to acquire Atrion aligns with this trend, as it seeks to strengthen its position in the medical sector and capitalize on long-term secular growth drivers such as the aging population and increasing healthcare spending.

Comparison to Industry Standards

• The valuation of 15x Atrion's FY2024 estimated EBITDA is within the typical range for acquisitions in the medical device industry, although the specific multiple can vary based on factors such as growth prospects, profitability, and strategic fit.
• Comparable transactions in the medical device space have seen EBITDA multiples ranging from 12x to 20x, depending on the target company's characteristics and the acquirer's strategic objectives.
• For example, Medtronic's acquisition of Mazor Robotics in 2018 was valued at approximately 19x Mazor's projected EBITDA, while Boston Scientific's acquisition of BTG in 2019 was valued at around 17x BTG's EBITDA.
• Given Atrion's established position in niche cardiovascular and infusion fluid delivery markets, the 15x multiple appears reasonable, especially considering the synergies Nordson expects to achieve.

Stakeholder Impact

• Atrion's stockholders are expected to receive $460 per share in cash.
• Nordson's shareholders may benefit from the expanded medical portfolio and expected synergies.
• Atrion's employees are expected to become part of Nordson MEDICAL.
• Customers of both Nordson and Atrion may benefit from a more comprehensive offering of solutions.
• The acquisition could impact suppliers and other business partners of both companies.

Next Steps

• Atrion expects to file a proxy statement with the SEC and mail it to its stockholders.
• Atrion's stockholders will vote on the transaction.
• The transaction is subject to regulatory approvals.
• Nordson will integrate Atrion's operations into its Medical & Fluid Solutions segment.
• Nordson will leverage its NBS Next growth framework to drive operational synergies and future growth.

Key Dates

Keywords

acquisition, Nordson, Atrion, medical, merger, EBITDA, synergies, infusion, cardiovascular, FDA